CDSCO panel grants clearance to Morepen Labs to conduct BE studies for fatty liver disease drug Resmetirom
Gurugram: Morepen Laboratories Ltd. has received clearance from the Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (‘BE’) studies for Resmetirom 60 mg, 80 mg and 100 mg tablets as per the protocol submitted.
This will be followed by clinical trials as per approved protocols.
Resmetirom is a highly promising therapy under development for non-alcoholic steatohepatitis (‘NASH’), a serious form of non-alcoholic fatty liver disease (‘NAFLD’) characterized by inflammation, liver damage, and fat accumulation in the liver, potentially leading to scarring (fibrosis), cirrhosis, and even liver cancer. It is often associated with obesity, metabolic syndrome, and type 2 diabetes, and while it can be a silent disease in the early stages, it can progress to severe liver damage if left untreated.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.